PB 203
Alternative Names: PB-203Latest Information Update: 03 Oct 2023
At a glance
- Originator Panolos Bioscience
- Class Antineoplastics; Immunoglobulin Fc fragments; Recombinant fusion proteins
- Mechanism of Action Placenta growth factor inhibitors; Programmed cell death-1 ligand-1 inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 26 Sep 2023 PB 203 is available for licensing as of 26 Oct 2023. https://www.panolos.com/ko/partner/partnership
- 26 Sep 2023 Preclinical trials in Solid tumours in South Korea prior to September 2023 (Intraperitoneal, Injection)
- 26 Sep 2023 Panolos Bioscience plans a phase I trial for Solid tumors in USA